Pomiferin
Based on 1 publication(s) in Google Scholar
Pomiferin (NSC 5113) acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 µM).
For research use only. We do not sell to patients.
- Purity: 98.01%
- CAS No.: 572-03-2
- Formula: C25H24O6
- Molecular Weight:420.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Pomiferin
More
Biological Activity
|
HDAC 1.05 μM (IC50) |
mTOR 6.2 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ACHN | GI50 |
3.18 μM
Compound: 2, Pomiferin
|
Growth inhibition of human ACHN cells after 21 hrs by MTT assay
Growth inhibition of human ACHN cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| BMDM | IC50 |
13 μg/mL
Compound: 134
|
Antiinflammatory activity in LPS-stimulated mouse BMDM cells assessed as inhibition of NF-kappaB signalling pathway incubated for 3 hrs by Western blot analysis
Antiinflammatory activity in LPS-stimulated mouse BMDM cells assessed as inhibition of NF-kappaB signalling pathway incubated for 3 hrs by Western blot analysis
|
[PMID: 37683361] |
| HCT-15 | GI50 |
1.32 μM
Compound: 2, Pomiferin
|
Growth inhibition of human HCT15 cells after 21 hrs by MTT assay
Growth inhibition of human HCT15 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| HeLa | IC50 |
1.05 μM
Compound: 2, Pomiferin
|
Inhibition of HDAC in HeLa cells
Inhibition of HDAC in HeLa cells
|
[PMID: 17662606] |
| Hepatocyte | GI50 |
123 μM
Compound: 2, Pomiferin
|
Growth inhibition of human hepatocytes after 21 hrs by MTT assay
Growth inhibition of human hepatocytes after 21 hrs by MTT assay
|
[PMID: 17662606] |
| LOX IMVI | GI50 |
3.34 μM
Compound: 2, Pomiferin
|
Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay
Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| MDA-MB-231 | GI50 |
2.92 μM
Compound: 2, Pomiferin
|
Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| NCI-H23 | GI50 |
5.14 μM
Compound: 2, Pomiferin
|
Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay
Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| PC-3 | GI50 |
3.95 μM
Compound: 2, Pomiferin
|
Growth inhibition of human PC3 cells after 21 hrs by MTT assay
Growth inhibition of human PC3 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| RAW264.7 | IC50 |
6.4 μg/mL
Compound: 134
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS mRNA expression
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS mRNA expression
|
[PMID: 37683361] |
Pomiferin is an potential inhibitor of HDAC, with an IC50 of 1.05 μM. Pomiferin shows cytotoxic effects on human tumor cell lines, with GI50s of 1.32 ± 0.02 μM (HCT-15 cells), 2.92 ± 0.09 μM (MDA-MB-231 cells), 3.18 ± 0.05 μM (ACHN cells), 3.34 ± 0.11 μM (LOX-IMVI cells), 3.95 ± 0.05 μM (PC-3 cells), 5.14 ± 0.06 μM (NCI-H23 cells), and 123 μM (Hepatocyte cells)[1]. Pomiferin is a highly specific mTOR inhibitor, with an IC50 of 6.2 µM. Pomiferin triacetate only affects two PI3Kα mutants, E542K and E545K. Pomiferin triacetate (0.3125-20 µM) stabilizes Pdcd4 from TPA-induced degradation in HEK293 cells. Pomiferin triacetate (20 µM) inhibits IGF-1-induced signaling downstream of Akt activation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 572-03-2
-
Appearance Solid
-
Molecular Weight 420.45
-
Formula C25H24O6
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C(O)C(C/C=C(C)\C)=C3C(C=CC(C)(C)O3)=C2OC=C1C4=CC=C(O)C(O)=C4
-
Synonyms
NSC 5113
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Pomiferin targeting SLC9A9 based on histone acetylation modification pattern is a potential therapeutical option for gastric cancer with high malignancy. [Abstract]2024 May 31:116333. PMID: 38824966
Solvent & Solubility
DMSO : 8.5 mg/mL (20.22 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Cell lines purchased from ATCC are maintained in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 10% horse serum and 5% fetal bovine serum and incubated in a CO2 incubator (5%) at 37°C. Cells are serum-deprived by three washes of PBS and resuspended in DMEM. The suspended cells are plated on 96-well plates (1 × 104 cells/well) and treated with Pomiferin. After treatment for 21 h, MTT is added to the medium (0.5 mg/mL), and the mixture is incubated at 37°C for another 3 h. After discarding the medium, DMSO (100 mL) is then applied to the well to dissolve the formazan crystals, and the absorbances at 570 and 630 nm in each well are measured on a micro-ELISA reader[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[3]
Male Wistar SPF laboratory rats are used in the study. After 10 days of acclimation, 50 animals are randomised in 5 groups (n=10). One group is left intact. Four groups undergo laparotomy in general anaesthesia (2% Rometar (xylazine) 0.5 mL + Narkamon (ketamine) 10 mL, dose 0.5 mL solution /100 g of body mass). Ischaemia-reperfusion injury is induced by applying a vascular clamp on the left renal artery for 60 min with subsequent renal reperfusion. Each animal (including those of the intact group) is put into its own metabolic cage. For 15 days all the animals are bred in these cages. The doses of pomiferin are suspended in 2 mL of 0.5% Avicel solution (microcrystalline cellulose) and are administered starting with day 1 after operation. Three of four operated groups are medicated with Pomiferin-orally by gastric gavage once a day in different doses: 5 mg/kg, 10 mg/kg and 20 mg/kg. The placebo group is given 2 mL of 0.5% Avicel by the same route. On day 15, all the animals are exsanguinated in general anaesthesia (2% Rometar 0.5 mL + Narkamon 10 mL, dose 0.5 mL solution /100 g of the rat body mass) by blood collection from the left ventricle and the reperfused kidney tissue is employed for histopathological examination[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Son IH, et al. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4753-5. [Content Brief]
[2]. Bajer MM, et al. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochem Pharmacol. 2014 Apr 1;88(3):313-21. [Content Brief]
[3]. Bartošíková L, et al. Effect of pomiferin administration on kidney ischaemia-reperfusion injury in rats. Interdiscip Toxicol. 2010 Jun;3(2):76-81. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3784 mL | 11.8920 mL | 23.7840 mL | 59.4601 mL |
| 5 mM | 0.4757 mL | 2.3784 mL | 4.7568 mL | 11.8920 mL | |
| 10 mM | 0.2378 mL | 1.1892 mL | 2.3784 mL | 5.9460 mL | |
| 15 mM | 0.1586 mL | 0.7928 mL | 1.5856 mL | 3.9640 mL | |
| 20 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL | 2.9730 mL |